Year: 2010
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: Metformin is associated with reduced cancer-related morbidity and mortality. The aim of this study was to assess the effect of metformin on cancer incidence in a consecutive series of insulin-treated patients. RESEARCH DESIGN AND METHODS: A nested case-control study was performed in a cohort of 1,340 patients by sampling, for each case subject, age-, sex-, and BMI-matched control subjects from the same cohort. RESULTS: During a median follow-up of 75.9 months, 112 case patients who developed incident cancer and were compared with 370 control subjects. A significantly lower proportion of case subjects were exposed to metformin and sulfonylureas. After adjustment for comorbidity, glargine, and total insulin doses, exposure to metformin, but not to sulfonylureas, was associated with reduced incidence of cancer (odds ratio 0.46 [95% CI 0.25-0.85], P = 0.014 and 0.75 [0.39-1.45], P = 0.40, respectively). CONCLUSIONS: The reduction of cancer risk could be a further relevant reason for maintaining use of metformin in insulin-treated patients.
Source: Diabetes Care
DOI: 10.2337/dc10-1287
Authors: Matteo Monami, Claudia Colombi, Daniela Balzi, Ilaria Dicembrini, Stefano Giannini, Cecilia Melani, Valentina Vitale, Desiderio Romano, Alessandro Barchielli, Niccolò Marchionni, Carlo Maria Rotella, Edoardo Mannucci
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Funders: Eli Lilly and Company, Sanofi, Novo Nordisk
OpenAlex ID: W2127753192
